Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.
Type:
Application
Filed:
December 13, 2002
Publication date:
July 3, 2003
Applicant:
CircaGen Pharmaceutical, a Delaware corporation
Inventors:
Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L. Wiech
Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.
Type:
Application
Filed:
December 26, 2001
Publication date:
October 3, 2002
Applicant:
CircaGen Pharmaceutical, a Delaware corporation
Inventors:
Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L. Wiech